Clinical trials: Sirolimus
Non-Small Cell Lung Cancer
Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC
The purpose of this study is to understand the effects (good and/or bad) of the addition of RAD001 to standard radiation and chemotherapy (cisplatin and pemetrexed) for patients with non-small cell lung cancer.
- Trial name
- RAD001 (NCT01063478)
- Testing
- RAD001 (in addition to standard radiation and chemotherapy)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Bladder Cancer
Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer
The study is a multi-site Phase 3 double-blinded randomized placebo-controlled trial. Subjects are randomly assigned to receive either a placebo or oral Sirolimus: 0.5 mg daily.
- Trial name
- NCT03298958
- Testing
- Rapamycin
- Where
- United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Peripheral Arterial Occlusive Disease, Bypass Complication
The SIR-POBA Bypass Trial
The goal of this clinical trial is to compare plain old balloon angioplasty with sirolimus-coated balloon angioplasty in patients with an infrainguinal venous bypass stenosis.
- Conditions
- Peripheral Arterial Occlusive Disease, Bypass Complication, Femoropopliteal Artery Occlusion, Femoropopliteal Stenosis
- Trial name
- NCT06056193
- Testing
- Balloon Angioplasty
- Where
- Austria
- Sponsor
- Paracelsus Medical University
Posttraumatic Stress Disorder
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory
The purpose of the proposed study is to determine if pairing reactivation of a traumatic memory with a single administration of Rapamycin (e.g., Sirolimus) in men with combat-related Posttraumatic Stress Disorder leads to a…
- Trial name
- NCT01449955
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Texas Southwestern Medical Center
Coronary Artery Disease, Coronary Restenosis
Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation
The purpose of the present study is to provide the first in-human safety and efficacy evaluations of systemic oral anti-proliferative Everolimus therapy compared to placebo in patients treated by bare metal stents for significant…
- Trial name
- NCT00426049
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 484 people
- Sponsor
- German Heart Institute
Hepatocellular Carcinoma
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
This is a Phase I study, which means that the goal is to see if the combination of Temsirolimus and Sorafenib is safe in patients with Hepatocellular Carcinoma. Sorafenib is a standard treatment for Hepatocellular Carcinoma.
- Trial name
- NCT01008917
- Testing
- sorafenib with temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
The primary objective of this study is to determine if estrogen receptor-targeted therapy with fulvestrant used in combination with Everolimus is an effective and safe therapy for women with hormone receptor positive metastatic…
- Trial name
- BRE-43 (NCT00570921)
- Testing
- Everolimus, Fulvestrant
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mara Chambers
Renal Transplanted Recipients
SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus
The aim of this study is to assess the safety and efficacy of corticosteroid discontinuation versus cyclosporine micro emulsion discontinuation in recipients receiving reduced exposure cyclosporine micro emulsion and…
- Trial name
- NCT00371826
- Testing
- Everolimus (RAD001), Cyclosporine (Calcineurin Inhibitor (CNI)), Methylprednisone/prednisone
- Where
- 7 sites in Australia
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Hematological Malignancies, Myelodysplastic Syndrome
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
The goal of this clinical research study is to learn if the combination of rabbit anti-thymocyte globulin (Thymoglobulin®), sirolimus (Rapamune®), and mycophenolate mofetil (Cellcept®) can help to prevent graft versus host…
- Conditions
- Hematological Malignancies, Myelodysplastic Syndrome, Leukemia, Lymphoma
- Trial name
- NCT00506948
- Testing
- Mycophenolate Mofetil (MMF), Thymoglobulin, Sirolimus
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Transplantation
Study Comparing Standard Dose and Reduced Dose Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients
This study evaluated renal graft function based on calculated creatinine clearance at 6 months after transplantation in patients receiving a regimen of 'reduced' or 'standard' dose tacrolimus plus sirolimus and corticosteroids.
- Trial name
- NCT00518271
- Testing
- Rapamune® (Sirolimus), Tacrolimus, Corticosteroids
- Volunteers
- 120 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of panobinostat and everolimus when given together and to see how well they work in treating patients with multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00918333
- Testing
- panobinostat, everolimus, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Mayo Clinic
Neuroendocrine Tumors
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in…
- Trial name
- COMPOSE (NCT04919226)
- Testing
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 259 people
- Sponsor
- ITM Solucin GmbH
Port Wine Stains
Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains
The goal of this clinical trial is to learn if the use of rapamycin cream can be used as a treatment together with pulsed dyed laser in treating port wine stain birthmarks.
- Trial name
- NCT07436611
- Testing
- Rapamycin cream, Pulsed dyed laser
- Where
- 2 sites in United States, Spain
- Volunteers
- 30 people
- Sponsor
- AFT Pharmaceuticals, Ltd.
Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL)
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
This is a multi-center, single arm Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated bone marrow transplantation donors and post-transplantation cyclophosphamide…
- Conditions
- Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma
- Trial name
- NCT02793544
- Testing
- Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Kidney Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
RATIONALE: Vatalanib and everolimus may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- PTK/RAD (NCT00303732)
- Testing
- RAD001 (everolimus), PTK787 (vatalanib)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Daniel George, MD
Coronary Atherosclerosis
Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions
The purpose of this study is to evaluate the safety and effectiveness of the Conor Sirolimus-eluting Coronary Stent System in the treatment of coronary artery disease (a single atherosclerotic lesion) in native coronary arteries.
- Trial name
- NEVO RES-I (NCT00606333)
- Testing
- NEVO™ Sirolimus-eluting Coronary Stent System, Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)
- Where
- 2 sites in Brazil, New Zealand
- Volunteers
- 394 people
- Sponsor
- Cordis US Corp.
Liver Cancer
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
RATIONALE: Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01005199
- Testing
- everolimus, sorafenib tosylate
- Where
- 15 sites in Austria, Hungary and 1 more
- Volunteers
- 106 people
- Sponsor
- Swiss Cancer Institute
AML
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
The purpose of this study is to evaluate the addition of Sirolimus (rapamycin) to standard chemotherapy for the treatment of patients with high risk acute myelogenous leukemia (AML).
- Trial name
- NCT01184898
- Testing
- Sirolimus, Mitoxantrone, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Fallopian Tube Cancer, Peritoneal Cavity Cancer
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pegylated liposomal doxorubicin hydrochloride (PLD) work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Conditions
- Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT01281514
- Testing
- everolimus, carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Metastatic Breast Cancer, ER-positive Breast Cancer
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
This is a Phase 1b open-label, 2-part study in 4 treatment groups. The 4 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation).
- Conditions
- Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer
- Trial name
- NCT05508906
- Testing
- Palazestrant, Ribociclib, Alpelisib
- Where
- 16 sites in United States, Australia
- Volunteers
- 190 people
- Sponsor
- Olema Pharmaceuticals, Inc.